We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » China’s Medical Device Market: Opportunities for U.S. Industry ‘Better than Ever’
[SPONSORED CONTENT]

China’s Medical Device Market: Opportunities for U.S. Industry ‘Better than Ever’

July 20, 2017

By Michael Levin-Epstein

With double-digit growth for over a decade, China’s medical device market is one of the fastest growing sectors in the country. Many view China as a priority market with strong demand, an improved regulatory environment, and a number of new business opportunities.

The U.S. Trade and Development Agency (USTDA) is connecting American companies to these opportunities. On July 25, 2017, USTDA is hosting a workshop where U.S. providers can meet with 22 senior officials from China’s Food and Drug Administration (CFDA), the agency that regulates medical devices, food, and pharmaceuticals.

Currently, China is working to streamline the process of importing medical devices, which includes allowing U.S. providers to produce their devices in China and collaborate with local manufacturers.

This is good news for U.S. companies looking to access the market, although they still face challenges.

Progress and Improvement

“The approval process for medical devices is longer in China than in other countries, but it is improving,” says Jeffrey Gren, a former top official at the U.S. Department of Commerce, where he played a leading role in developing U.S.-China trade initiatives in the pharmaceutical and medical device space.

“Sometimes China requires duplicate inspections of manufacturing facilities, and there can be redundant testing,” Gren adds. “Also, China has been relatively slow to adopt standards after they are approved in other markets, which can cause a problem for manufacturers, with one set of criteria for most of the world, and another set for China.”

Another barrier to market entry involves additional clinical trial requirements, on top of those already met in the country of origin.

China is addressing some of these challenges and continues to make significant investments in healthcare reform. At USTDA’s workshop and corresponding training, leaders from CFDA will meet with U.S. experts who will share best practices and leading technologies that can help China achieve its goals.

Top Prospects for U.S. Companies

U.S. providers can approach new opportunities in China by partnering with local companies. They can also sell medical devices directly to China, manufacture components and parts in country, and work in collaboration with other U.S. companies to do business in country.

Currently, some of the best prospects in the medical device sector in China are:

  • In vitro diagnostic equipment and reagents
  • Orthopedic equipment and products
  • Implantable and intervention materials and artificial organs
  • Therapeutic products
  • Medical diagnostic and imaging equipment
  • Surgical and emergency appliances
  • Healthcare information technology-related equipment and products
  • Medical equipment parts and accessories

U.S. businesses can learn more about China’s medical device needs and goals at USTDA’s public-private workshop on July 25, 2017. This event presents a unique opportunity for the public and private sectors to meet with key CFDA officials and develop new business partnerships.

For more information on the workshop and to register, please visit http://phmintl.com/china-fda/.

View today's stories

Medical Devices

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing